CytRx Corp (CYTR) Reports Encouraging Data from Aldoxorubicin Phase 1b/2
Tweet Send to a Friend
CytRx Corporation (NASDAQ: CYTR) announced the presentation today of favorable results from a Phase 1b/2 clinical trial with its tumor-targeting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
